Special Issue

Mechanistic Insights of Selective Autophagy in Neurodegenerative Diseases

Message from the Guest Editors

Selectively targeting cytosolic components or organelles for degradation is a major surveillance mechanism employed in several cell types and animal models. Damaged organelles and protein aggregates are crucial hallmarks of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and so on. In this process, several selective autophagy receptors bind to the dysregulated cellular cargo via the Atg8/LC3/GABARAP proteins and promote their degradation. Modulating guality control mechanisms can alleviate the devastating effects of neurodegenerative diseases. This Special Issue will focus on recent advances in selective autophagy in neurodegenerative diseases, aiming to foster an improved understanding of the roles of selective autophagy in the pathogenesis, propagation, and therapeutics of various neurodegenerative diseases.

Guest Editors

Dr. Ashok Iyaswamy

Dr. Chun Kit Benjamin Tong

Dr. Sreenivasmurthy Sravan Gopalkrishnashetty

Deadline for manuscript submissions

closed (30 November 2023)



Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 5.2 Indexed in PubMed



mdpi.com/si/124041

Biomedicines MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 biomedicines@mdpi.com

mdpi.com/journal/ biomedicines





Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 5.2 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

 Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).